Biopsy | Age (years) | Sex | Disease duration (years) | RF/aCCP | Disease-modifying antirheumatic drugs | Joint | Valid samples/total samples | Valid sections | Cumulative area (mm2) |
---|---|---|---|---|---|---|---|---|---|
S-SY1 | 65 | Female | 18 | +/+ | MTX | Wrist | 3/3 | 9 | 24.47 |
S-SY2 | 44 | Female | 12 | -/- | PDN | I MTP | 3/3 | 9 | 37.72 |
S-SY3 | 63 | Female | 14 | +/+ | MTX + HCQ | II and III MTPs | 3/3 | 9 | 44.02 |
S-SY4 | 46 | Female | 34 | -/+ | HCQ | Wrist | 4/4 | 12 | 41.68 |
S-SY5 | 46 | Female | 17 | -/- | LFN + PDN | Wrist | 5/5 | 15 | 60.32 |
S-SY6 | 75 | Female | 7 | -/- | MTX + PDN | MCPs | 3/3 | 9 | 34.75 |
S-SY7 | 78 | Female | 8 | -/- | MTX + PDN | MCPs | 3/3 | 9 | 38.68 |
S-SY8 | 46 | Male | 2 | -/+ | MTX + PDN | MCPs | 3/3 | 9 | 22.42 |
S-SY9 | 68 | Female | 5 | -/- | MTX + HCQ + PDN | I MTP | 3/3 | 9 | 45.01 |
U-SY1 | 23 | Female | 5 | +/+ | CYA + PDN | II MCP | 4/8 | 12 | 16.86 |
U-SY2 | 59 | Female | 4 | -/- | MTX + PDN | V MCP | 5/8 | 15 | 17.64 |
U-SY3 | 64 | Female | 18 | +/+ | PDN | II PIP | 10/12 | 30 | 38.28 |
U-SY4 | 61 | Female | 11 | -/+ | MTX + PDN | V MCP | 3/12 | 9 | 7.29 |
U-SY5 | 69 | Male | 10 | +/+ | MTX + HCQ + PDN | II MCP | 8/12 | 24 | 20.16 |
U-SY6 | 75 | Male | 11 | +/+ | HCQ + SLZ + PDN | V MCP | 10/12 | 29 | 28.71 |
U-SY7 | 67 | Female | 7 | -/+ | MTX + HCQ + PDN | II MCP | 8/12 | 23 | 8.82 |
U-SY8 | 62 | Female | 8 | -/- | MTX + PDN | II MCP | 7/12 | 20 | 8.43 |
U-SY9 | 61 | Female | 11 | +/+ | MTX + HCQ + PDN | II MCP | 9/12 | 26 | 20.91 |